Core Points - The CoreWeave class action lawsuit involves allegations against CoreWeave, Inc. and its executives for violations of the Securities Exchange Act of 1934 during the Class Period from March 28, 2025, to December 15, 2025 [1] - The lawsuit claims that CoreWeave overstated its ability to meet customer demand and failed to disclose significant risks associated with its reliance on a single third-party data center supplier [3] - CoreWeave's stock price experienced significant declines following announcements related to merger agreements and lowered revenue guidance, indicating potential investor losses [4][5][6] Company Overview - CoreWeave is positioned as an AI cloud computing company and announced a deal worth up to $11.9 billion with OpenAI shortly before its IPO [2] - The company also aimed to acquire Core Scientific, a major player in digital infrastructure for high-performance computing, in an all-stock transaction [2] Allegations and Impact - The lawsuit alleges that CoreWeave's executives made misleading statements regarding the company's operational capabilities and the risks associated with its data center supplier [3] - Following the announcement of insufficient shareholder votes for the merger with Core Scientific, CoreWeave's stock fell by over 6% [4] - A subsequent announcement of lowered revenue guidance due to delays from a third-party data center provider led to a further decline of more than 16% in stock price [5] - Reports revealing greater-than-acknowledged delays in data center delivery resulted in an additional drop of 3.4% in CoreWeave's stock price [6]

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of PayPal Holdings, Inc. ("PayPal†or the "Company†) (NASDAQ: PYPL) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON PAYPAL HOLDINGS, INC. (PYPL), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On February 3, 2026, PayPal announced a surprise leadership ch. ...

Core Viewpoint - Investors in BellRing Brands, Inc. have the opportunity to lead a securities fraud class action lawsuit due to alleged misleading statements regarding the company's sales performance and inventory management [1][2]. Group 1: Lawsuit Details - The lawsuit claims that from November 19, 2024, to August 4, 2025, BellRing's management failed to disclose that strong sales results were not indicative of genuine consumer demand or brand momentum [2]. - It is alleged that customers built up excess inventory as a precaution against previous product shortages, which misrepresented the actual demand for BellRing's products [2]. - Once customers felt secure about product availability, they began to reduce their inventory, leading to a decline in new orders [2]. - Following this destocking phase, BellRing acknowledged that competitive pressures were significantly weakening demand for its products [2]. - The lawsuit asserts that the positive statements made by the company's management regarding its business and prospects were materially misleading and lacked a reasonable basis [2].

Core Viewpoint - The Law Offices of Frank R. Cruz is investigating Corcept Therapeutics Incorporated for potential violations of federal securities laws on behalf of investors who may have incurred losses [1] Group 1 - The investigation is focused on Corcept Therapeutics Incorporated (NASDAQ: CORT) and its compliance with federal securities regulations [1] - Investors who lost money on Corcept Therapeutics are encouraged to inquire about pursuing claims to recover their losses [1]

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Ultragenyx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class acti ...

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc (“Mereo” or the “Company”) (NASDAQ: MREO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Mereo and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] During pre- ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving First Citizens BancShares and its officers or directors, following disappointing financial results and a significant stock price drop [1][3][4]. Financial Performance - On January 23, 2026, First Citizens reported its fourth-quarter financial results for 2025, revealing an efficiency ratio of 64.5%, which missed analyst expectations and worsened compared to the previous year [3]. - The company provided a weaker outlook, indicating expected deterioration in revenue and weak projections for net interest income in the upcoming year [3]. Stock Market Reaction - Following the announcement of the financial results, First Citizens' stock price fell by $186.97 per share, or 8.49%, closing at $2,016.56 per share on January 23, 2026 [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Capital One Financial Corporation and its officers or directors [1]. Financial Performance - On January 22, 2026, Capital One reported Q4 2025 earnings per share of $3.86, which fell short of analyst expectations of $4.14 [3]. - The company's efficiency ratio was reported at 60%, also missing analyst expectations [3]. - Following the earnings report, Capital One's stock price dropped by $17.77, or 7.56%, closing at $217.30 per share on January 23, 2026 [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving BlackRock TCP Capital Corp and its officers or directors [1] Group 1: Company Performance - On January 23, 2026, BlackRock TCP reported a 19% decline in the net asset value of its private corporate loans, attributed to a significant increase in nonperforming loans [3] - Following this announcement, BlackRock TCP's stock price decreased by $0.76 per share, representing a 12.97% drop, closing at $5.10 per share on January 26, 2026 [3] Group 2: Legal Investigation - Pomerantz LLP is reaching out to investors of BlackRock TCP to discuss claims related to the company's potential involvement in securities fraud [1] - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action [2]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Corcept Therapeutics and its officers or directors, following a significant stock price drop after the FDA's Complete Response Letter regarding a new drug application [1][3]. Group 1: Company Overview - Corcept Therapeutics Incorporated is a biopharmaceutical company focused on developing treatments for patients with conditions related to cortisol excess [3]. - The company’s stock price experienced a dramatic decline of $35.40 per share, or 50.42%, closing at $34.80 per share on December 31, 2025, after the FDA issued a Complete Response Letter regarding its drug relacorilant [3]. Group 2: Regulatory Developments - On December 31, 2025, the FDA issued a Complete Response Letter concerning Corcept's New Drug Application for relacorilant, indicating that while the pivotal GRACE trial met its primary endpoint, additional evidence of effectiveness was required for a favorable benefit-risk assessment [3]. Group 3: Legal Investigation - Pomerantz LLP, a prominent firm in corporate and securities class litigation, is currently investigating claims on behalf of investors of Corcept, suggesting potential legal ramifications for the company and its leadership [1][4].